A 28-day clinical trial with 31 subjects compared a 0.1 % pterostilbene skincare emulsion to a control using a double-blind, split-face design. Advanced tools and self-assessments showed the pterostilbene emulsion significantly improved skin elasticity, reduced wrinkles, and increased epidermis thickness and collagen intensity. It outperformed the control in multiple metrics (p < 0.05) and gained higher subject satisfaction, highlighting its potent anti-aging effects and value in cosmetics.

Foundation models in molecular biology, leveraging their success in NLP and image generation, are revolutionizing the understanding of multi-level molecular correlations by training on vast datasets encompassing RNA/DNA/protein sequences, single-cell transcriptomics, and spatial transcriptomics. These models decode intricate relationships (e.g., gene regulatory networks, protein interaction hubs) to predict functions, design therapeutics, and infer spatial tissue dynamics. Current frameworks include ESM-2 (protein structure-function prediction), scGPT (single-cell data integration), and DNABERT (genomic variant interpretation). Future directions emphasize multimodal integration (combining sequences, structures, and omics), interpretable attention mechanisms for biological insights, and scalable architectures for high-resolution spatial-temporal data. Addressing data heterogeneity and model generalizability will unlock precision biomedicine applications.

Recently, a research team led by Dr. Tida Ge from Xinjiang University and Ningbo University conducted a pot experiment to explore this question. The study selected peas as the experimental crop and examined two types of microplastics: traditional microplastics (polypropylene (PP) and polyethylene (PE)) and biodegradable microplastics (polycaprolactone (PCL) and polybutylene adipate terephthalate (PBAT)). These were added to the soil at doses of 0%, 0.1%, and 1% (w/w) to observe the growth status of peas during three critical growth stages: seedling, flowering, and maturity. The study also analyzed soil nutrients, microbial activity, and community changes. The study has been published in Frontiers of Agricultural Science and Engineering (DOI: 10.15302/J-FASE-2025626).

Objective

Deep venous thrombosis (DVT), a potentially life-threatening condition with a high clinical incidence, represents a significant healthcare burden in China. This study aims to investigate the prevalence of protein C (PROC) p.Lys193del mutation and promoter polymorphisms in patients with DVT in Shanghai, China.

Methods

A total of 180 patients diagnosed with DVT and 103 healthy controls underwent polymerase chain reaction amplification targeting two specific regions of the PROC gene for genetic analysis of the p.Lys193del mutation and promoter polymorphisms.

Results

The p.Lys193del mutation was significantly more prevalent in the DVT group, with 13 carriers identified (7.2​%, 13/180), compared to only one carrier in the control group (0.97%, 1/103; P<0.05). Genetic analysis of PROC promoter polymorphisms revealed distinct allele distribution patterns between the groups, with significantly different frequencies for the −1654 ​C,−1641 ​G and −1476 ​T alleles in DVT group versus control group (P<0.05). Corresponding genotype analysis showed significant intergroup differences in the three homozygous variants: −1654C/C, −1641G/G and −1476T/T, all of which exhibited significantly higher frequencies in the DVT group compared to control group (11.1% vs. 1.9%, P<0.01).

Conclusions

The PROC p.Lys193del mutation, an established genetic risk factor for DVT, accounts for about 7.2% of DVT cases. Furthermore, three promoter polymorphisms (−1654C/C, −1641G/G, −1476T/T) were present as homozygous genotypes in 6.1% (11/180) of DVT group, demonstrating statistically significant association with thrombotic risk compared to healthy controls (P<0.05). These findings position both the p.Lys193del mutation and the promoter haplotype variants as independent genetic risk factors for venous thromboembolism in the studied population.

In a landmark move to bridge global medical innovation, LabMed Discovery has opened its first international office at the University of Rome Tor Vergata. This strategic partnership, formalized with a signing ceremony attended by Chinese and Italian delegates, promises to accelerate collaborative research and journal visibility worldwide. The office underscores China’s commitment to fostering cross-border scientific dialogue and journal excellence.

Radiopharmaceuticals have become indispensable tools in precision medicine, revolutionizing diagnostic imaging and targeted therapeutic strategies. This manuscript provides an overview of advancements globally and in China, focusing on the classification and clinical applications of radiopharmaceuticals, particularly in oncology and neurology. Recent progress includes PET/SPECT diagnostic agents and therapeutic radionuclides that provide precise treatment while limiting damage to healthy tissues. Emerging technologies, such as artificial intelligence, novel ligands, advanced radionuclides, and combination therapies, present promising avenues to further enhance the efficacy and accessibility of the field. Despite these achievements, challenges remain in production, regulatory, and costs, underscoring the need for ongoing innovation and international collaboration to fully realize the potential of radiopharmaceuticals in personalized healthcare and optimize patient outcomes.